Form 4: Poplar Point Capital Partners LP Increases Stake in NovaBay Pharmaceuticals

Poplar Point Capital Partners LP, along with related entities and Jad Fakhry, reports acquiring additional shares of NovaBay Pharmaceuticals, increasing their holdings to over 1 million shares.

Summary

• Poplar Point Capital Partners LP, Poplar Point Capital Management LLC, Poplar Point Capital GP LLC, and Jad Fakhry jointly filed a Form 4.
• The filing reports purchases of NovaBay Pharmaceuticals common stock between April 2, 2025, and April 8, 2025.
• The purchases increased Poplar Point Capital Partners LP's direct holdings to 1,020,300 shares.
• The shares were acquired at prices ranging from $0.465 to $0.58 per share.
• Jad Fakhry is the manager of PPCM and PPCGP, and owns a controlling interest in, PPCM and PPCGP.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The increased stake suggests confidence, but it's a routine filing.

Positives

• Poplar Point Capital Partners LP increased its holdings in NovaBay Pharmaceuticals, which could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell shares. These filings are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• The increased stake by Poplar Point Capital Partners LP could positively influence shareholder sentiment.

Key Dates

Keywords

NovaBay Pharmaceuticals, Poplar Point Capital Partners, Form 4, Beneficial Ownership, Stock Acquisition, NBY, Jad Fakhry